X4 Pharmaceuticals

Edit info

Founded: 2012

Location: Boston, MA

Employee range: 50 - 200

Clinical stage: NDA

Therapy area: WHIM syndrome

Drug types: GEN, IMM, RAR, INF, DRM, PED, HEM, ONC

Lead product: Mavorixafor

Funding: $65M stock May 2023; $65M stock Dec 2022; $55M stock Jun 2022; $55M stock Mar 2021; $27M Nov 2017

x4pharma.com

linkedin.com

job board

Drug notes:

Also Clin2 multiple neutropenias, Clin1b Waldenstrom's macroglobulinemia; X4P-002 Clin0 oncology; X4P-003 Clin0 neutropenic disorder

About:

X4 Pharmaceuticals is developing novel small molecule therapies that target the X4 receptor. The X4 receptor is a G protein-coupled receptor (GPCR) that plays a key role in the inflammatory response. When the X4 receptor is activated, it signals for the recruitment of leukocytes, which are white blood cells that help to fight infection and repair damaged tissue. However, overactivation of the X4 receptor can lead to chronic inflammation, which is associated with a variety of diseases, including fibrosis. X4 Pharmaceuticals' X4 receptor modulators are designed to selectively modulate the X4 receptor to reduce inflammation and fibrosis without causing unwanted side effects.